Fluorogenic platinum(<scp>iv</scp>) complexes as potential predictors for the design of hypoxia-activated platinum(<scp>iv</scp>) prodrugs-Reference-Cited by-同舟云学术

Fluorogenic platinum(iv) complexes as potential predictors for the design of hypoxia-activated platinum(iv) prodrugs

Published:2024 Issue:35 Volume:53 Page:14811-14816
ISSN:1477-9226
Container-title:Dalton Transactions
language:en
Short-container-title:Dalton Trans.

Author:

Marsh Jevon W.¹,Hacker Lina²^ORCID,Huang Shitong¹,Boulet Marie H. C.¹,White Jhanelle R. G.³,Martin Louise A. W.²,Yeomans Megan A.¹,Han Hai-Hao⁴^ORCID,Diez-Perez Ismael³^ORCID,Musgrave Rebecca A.³^ORCID,Hammond Ester M.²^ORCID,Sedgwick Adam C.¹³^ORCID

Affiliation:

1. Chemistry Research Laboratory, University of Oxford, Mansfield Road, OX1 3TA, UK

2. Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK

3. Department of Chemistry, King's College London, 7 Trinity Street, London, SE1 1DB, UK

4. Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, P. R. China

Abstract

In this work, we have developed and demonstrated the utility of fluorogenic Pt(IV) complexes to help predict the design of a hypoxia-activated platinum(IV) (HAPt) prodrug.

Funder

University of Oxford

Jesus College, University of Oxford

King’s College London

Engineering and Physical Sciences Research Council

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/DT/D4DT02173H

Reference44 articles.

1. Platinum-based drugs for cancer therapy and anti-tumor strategies

2. The side effects of platinum-based chemotherapy drugs: a review for chemists

3. Cisplatin in cancer therapy: Molecular mechanisms of action

4. The status of platinum anticancer drugs in the clinic and in clinical trials

5. Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents